Investors & Media

Investors & Media

Corporate Profile

Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and cancer-supportive care by targeting high-value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancer and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizer’s palbociclib (Ibrance®) for the treatment of MDM2-amplified advanced solid tumors, and in a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. 

More >>

Stock

Copyright West LLC. Minimum 15 minutes delayed.

Recent News

Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harbor...
WATERTOWN, Mass. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Compa...
Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy ALRN-6924 could enable a precisi...

Upcoming Events

More events are coming soon.

Investor Contacts

Rick Wanstall

Vice President, Finance and Operations

rwanstall@aileronrx.com

LifeSci Advisors, LLC.

Hans C. Vitzthum

617-535-7743

hans@lifesciadvisors.com